Gladius Pharmaceuticals
Wilmington, US · Founded 2015 · Delaware corporation
Founders & leadership
MA
Michael AtkinExecutive
Reported raises · per SEC filings
Form D private placements$3.8M disclosed across 2 rounds · 2015–2018
▶$3MraisedNov 2018 · 5 investors · BiotechnologyRule 506(b)
▶$3MraisedNov 2018 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael AtkinExecutive Officer
- Nathalie ChauretDirector
- Larry SuttonDirector
- Jens EcksteinDirector
- Daniel HetuDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$727.8KraisedJun 2015 · 2 investors · PharmaceuticalsRule 506(b)
▶$727.8KraisedJun 2015 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael AtkinExecutive Officer, Director
- Offering amount
- $727.8K
- Amount sold
- $727.8K
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Gladius Pharmaceuticals raised?
- Gladius Pharmaceuticals has disclosed $3.8M raised across 2 rounds.
- Where is Gladius Pharmaceuticals headquartered?
- Gladius Pharmaceuticals is headquartered in Wilmington, US.